Senolytic Fisetin Protocol

THE MECHANICS

Senescent cells are the culprits behind tissue dysfunction in aging and age-related diseases. These cells stop dividing but remain viable, altering their gene expression and resisting apoptosis. The SASP phenotype is where senescence reveals its dark side: secretion of inflammatory cytokines, chemokines, growth factors, proteases, and extracellular matrix remodeling enzymes. This cocktail creates a toxic environment that leads to tissue damage and disease progression. Additionally, these cells secrete VEGF, driving angiogenesis in lung cancer and facilitating tumor growth.

THE BIOLOGICAL LEVERAGE

Fisetin steps up as the eliminator of senescent cells, particularly effective in conditions like sepsis. By targeting SASP-related maladaptive signaling pathways, it curtails inflammatory responses linked to aging and diseases such as sepsis. This clearance not only reduces inflammation but also enhances the efficacy of chemotherapy when combined with treatment regimens for lung cancer. Post-treatment senescent cells that linger become prime targets for fisetin’s precision clearance.

THE TACTICAL IMPLEMENTATION

Dosing matters in maximizing the protocol's impact. Administering a single oral dose of 20 mg/kg or two spaced doses, one day apart, can be tailored based on individual response and condition severity. This dosing strategy ensures that senescent cells are efficiently cleared without overwhelming the system, providing sustained benefits over time.

Do your own research. Don't be a statistic.